MediPharm Labs (TSXV:LABS; OTCQB:MEDIF) appointed Braden Fenske as chief strategy officer and Dr. Paul Tam to its board of directors, effective immediately.
Mr. Fenske has more than 20 years of experience in pharmaceuticals and medical devices. He was most recently group product director of global strategic marketing at Biosense Webster, a Johnson & Johnson company. Mr. Fenske also gained experience in the adult beverage industry at Mark Anthony Brands and Molson Coors Brewing.
“Braden’s proven record of success developing operational growth strategies, his unique understanding of the pharmaceutical and medical delivery systems industry, and his U.S. and worldwide healthcare relationships, will strengthen MediPharm Labs’ position as a trusted partner for customers, and clinical trials, as we remain at the leading edge of the industry and achieve our growth potential in this rapidly evolving market,” Patrick McCutcheon, MediPharm’s CEO, said in a statement.
Dr. Tam is an expert in the field of nephrology and a pioneer of continuous renal replacement therapy for acute kidney injury. He is the medical director of the Scarborough Regional Nephrology Program, which he founded in 1996. Dr. Tam was most recently a director of Biovail and also served as the medical director of Biovail’s contract research arm.
“Dr. Paul Tam is a tremendous addition to our board and will be a valuable independent director and contributor as we continue to deepen our medical expertise through this next phase of growth,” McCutcheon added.
MediPharm is a licensed producer of cannabis, focused on extraction and purification. The company is developing purified, pharmaceutical-like cannabis oils and concentrates for the adult-use market.
